滚动资讯
FierceBiotechGilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for GalapagosFierceBiotechAardvark halts trials of obesity candidate, putting entire pipeline on pauseFierceBiotechInnovent sees path to China approval after eye disease drug matches Eylea in phase 3FierceBiotechMerck hands over $20M in IBD drug target deal with Flagship's QuotientCytiva (Google News)Cytiva and Yoshindo advance domestic biosimilar manufacturing in Japan - BioSpectrum AsiaEndpoints NewsApnimed set to exit sleep disorder joint venture with Shionogi for $100M upfrontBioPharma DiveHow former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startupAgilentSG Americas Securities LLC持有安捷伦科技公司价值1.0997亿美元股份Endpoints NewsGilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch inEndpoints NewsMerck partners with Flagship startup Quotient to search for genetic clues to IBDThermo Fisher社区信托投资公司减持赛默飞世尔科技股份 $TMO - MarketBeatThermo Fisher卡德罗克资本管理公司购入5,662股赛默飞世尔科技公司股票$TMO - MarketBeat
Agilent 2026年3月23日

安捷伦科技 | 4：证券实益所有权变更声明 - 董事 WILSON DOW R - Moomoo

安捷伦科技 | 4：证券实益所有权变更声明 - 董事 WILSON DOW R - Moomoo

原文
暂时没有全文，请查看原始来源。

目录

59 全部